Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments.

Nuclear factor erythroid 2-related factor 2 (Nrf2) is involved in tumor drug resistance, but its role in imatinib resistance of chronic myeloid leukemia (CML) remains elusive. We aimed to investigate the effects of Nrf2 on drug sensitivity, thioredoxin reductase (TrxR) expression, reactive oxygen sp...

Descripción completa

Detalles Bibliográficos
Publicado en:BioMed Research International pp. 1 - 13
Autores principales: Xu, Lianrong, Zhao, Yan, Pan, Fei, Zhu, Mengxia, Yao, Liqin, Liu, Yan, Feng, Jiangfang, Xiong, Jie, Chen, Xiuhua, Ren, Fanggang, Tan, Yanhong, Wang, Hongwei
Formato: pictorial research tables/charts Journal Article
Publicado: Wiley-Blackwell 11/18/2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139734909&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 139734909
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        23146133
        FT2T
      jtl: BioMed Research International
      issn: 23146133
      maglogo: N
    pubinfo:
      dt: 11/18/2019
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        139734909
        139734909
        139734909
        10.1155/2019/6502793
        139734909
      ppf: 1
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments.
      aug:
        au:
          Xu, Lianrong
          Zhao, Yan
          Pan, Fei
          Zhu, Mengxia
          Yao, Liqin
          Liu, Yan
          Feng, Jiangfang
          Xiong, Jie
          Chen, Xiuhua
          Ren, Fanggang
          Tan, Yanhong
          Wang, Hongwei
        affil: Department of Hematology, 2nd Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China
      sug:
        subj:
          Leukemia, Myeloid, Chronic
          Transcription Factors
          Gene Expression
          Drug Resistance, Neoplasm
          Imatinib
          Cell Line, Tumor Physiology
          Reactive Oxygen Species
          Oxidoreductases
          Apoptosis
          Cell Proliferation
          Proteins Physiology
          Genotype
          Pharmacogenetics
          Polymorphism, Genetic
          Antineoplastic Agents Pharmacodynamics
          MicroRNA
          Flow Cytometry
          Polymerase Chain Reaction
          Blotting, Western
          Signal Transduction
      ab: Nuclear factor erythroid 2-related factor 2 (Nrf2) is involved in tumor drug resistance, but its role in imatinib resistance of chronic myeloid leukemia (CML) remains elusive. We aimed to investigate the effects of Nrf2 on drug sensitivity, thioredoxin reductase (TrxR) expression, reactive oxygen species (ROS) production, and apoptosis induction in imatinib-resistant CML K562/G01 cells and explored their potential mechanisms. Stable K562/G01 cells with knockdown of Nrf2 were established by infection of siRNA-expressing lentivirus. The mRNA and protein expression levels of Nrf2 and TrxR were determined by real-time quantitative polymerase chain reaction and western blot, respectively. ROS generation and apoptosis were assayed by flow cytometry, while drug sensitivity was measured by the Cell Counting Kit-8 assay. Imatinib-resistant K562/G01 cells had higher levels of Nrf2 expression than the parental K562 cells at both mRNA and protein levels. Expression levels of Nrf2 and TrxR were positively correlated in K562/G01 cells. Knockdown of Nrf2 in K562/G01 cells enhanced the intracellular ROS level, suppressed cell proliferation, and increased apoptosis in response to imatinib treatments. Nrf2 expression contributes to the imatinib resistance of K562/G01 cells and is positively correlated with TrxR expression. Targeted inhibition of the Nrf2-TrxR axis represents a potential therapeutic approach for imatinib-resistant CML.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N